Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
…, F Dentali, MA Crowther, RM Meyer… - Annals of internal …, 2007 - acpjournals.org
… 2 per dose (29); and 1 used a low dose of rituximab (50 mg/m 2 on day 1, then 150 mg/m 2
on days 8 and 15), an intermediate dose (150 mg/m 2 on day 1, then 375 mg/m 2 weekly for 3 …
on days 8 and 15), an intermediate dose (150 mg/m 2 on day 1, then 375 mg/m 2 weekly for 3 …
[HTML][HTML] ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma
RM Meyer, MK Gospodarowicz… - … England Journal of …, 2012 - Mass Medical Soc
Background Chemotherapy plus radiation treatment is effective in controlling stage IA or IIA
nonbulky Hodgkin's lymphoma in 90% of patients but is associated with late treatment-…
nonbulky Hodgkin's lymphoma in 90% of patients but is associated with late treatment-…
[PDF][PDF] Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous …
… Osoba D, Bezjak A, Brundage M, et al: Analysis and interpretation of health-related
quality of life data from clinical trials: Basic approach of the National Cancer Institute of …
quality of life data from clinical trials: Basic approach of the National Cancer Institute of …
[PDF][PDF] Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National …
RM Meyer, MK Gospodarowicz, JM Connors… - Journal of Clinical …, 2005 - Citeseer
… Address reprint requests to Ralph M. Meyer, MD, Division of Hematology, … Greenwood
M: A report on the natural duration of cancer: Report on public health and medical subjects …
M: A report on the natural duration of cancer: Report on public health and medical subjects …
Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial
…, WF Demas, CF Wilson, RM Meyer… - The Lancet …, 2014 - thelancet.com
Background Although repeat radiation treatment has been shown to palliate pain in patients
with bone metastases from multiple primary origin sites, data for the best possible dose …
with bone metastases from multiple primary origin sites, data for the best possible dose …
A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets
NM Heddle, MA Blajchman, RM Meyer, JH Lipton… - …, 2002 - Wiley Online Library
BACKGROUND: Removal of the plasma supernatant from platelets before transfusion is
effective in preventing acute reactions to platelets caused by cytokines. Prestorage WBC …
effective in preventing acute reactions to platelets caused by cytokines. Prestorage WBC …
Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled …
E Chow, RM Meyer, K Ding, A Nabid, P Chabot… - The Lancet …, 2015 - thelancet.com
Background Pain flare occurs after palliative radiotherapy, and dexamethasone has shown
potential for prevention of such flare. We aimed to compare the efficacy of dexamethasone …
potential for prevention of such flare. We aimed to compare the efficacy of dexamethasone …
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National …
…, L Shepherd, JAW Chapman, RM Meyer - Blood, The Journal …, 2013 - ashpublications.org
We conducted a randomized, controlled trial comparing thalidomide-prednisone as
maintenance therapy with observation in 332 patients who had undergone autologous stem cell …
maintenance therapy with observation in 332 patients who had undergone autologous stem cell …
Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML
PB Neame, P Soamboonsrup, GP Browman, RM Meyer… - 1986 - ashpublications.org
A panel of commercially available monoclonal antibodies and five heteroantisera were used
to distinguish and subtype 138 cases of acute leukemia (AL). The immunophenotype was …
to distinguish and subtype 138 cases of acute leukemia (AL). The immunophenotype was …
A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia
…, DJ Cook, MA Crowther, RM Meyer… - Blood, The Journal …, 2012 - ashpublications.org
The benefit of adding rituximab to standard treatment in nonsplenectomized patients with
primary immune thrombocytopenia (ITP) is uncertain. We performed a pilot randomized trial to …
primary immune thrombocytopenia (ITP) is uncertain. We performed a pilot randomized trial to …
